Brett R Hagen
CIK 1681782 · Chief Accounting Officer · last filed 2026-03-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
84
Lifetime Open-Market Net
-$728.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Chief Accounting Officer | 0 | $4.19 | $0 | -$21.0K | 3 | 2026-03-23 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Chief Accounting Officer | 2,832 | $9.81 | $27.8K | -$707.1K | 44 | 2025-02-24 |
| KINETA, INC./DE (PTI) Delisted | See Remarks | — | — | — | $0 | 2 | 2017-04-05 |
Recent Filings · Page 8 of 9
84 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-24 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −13,679 | -$115.3K | EDGAR |
| 2022-08-17 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2022-07-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +10,500 | $0 | EDGAR |
| 2022-04-22 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −276 | -$1.8K | EDGAR |
| 2022-04-04 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +17,442 | $0 | EDGAR |
| 2022-01-24 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −1,563 | -$13.7K | EDGAR |
| 2021-02-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −800 | -$34.5K | EDGAR |
| 2021-02-19 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −741 | -$29.7K | EDGAR |
| 2021-02-18 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −5,370 | -$221.6K | EDGAR |
| 2021-01-21 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +17,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.